

**SOX9 Antibody (N-term) Blocking Peptide**

Synthetic peptide  
Catalog # BP1409a

**Specification**

---

**SOX9 Antibody (N-term) Blocking Peptide - Product Information**

Primary Accession [P48436](#)

**SOX9 Antibody (N-term) Blocking Peptide - Additional Information**

Gene ID 6662

**Other Names**

Transcription factor SOX-9, SOX9

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP1409a](/product/products/AP1409a) was selected from the N-term region of human SOX9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SOX9 Antibody (N-term) Blocking Peptide - Protein Information**

**Name** SOX9 {ECO:0000303|PubMed:7990924, ECO:0000312|HGNC:HGNC:11204}

**Function**

Transcription factor that plays a key role in chondrocytes differentiation and skeletal development (PubMed:[24038782](http://www.uniprot.org/citations/24038782)). Specifically binds the 5'-ACAAAG-3' DNA motif present in enhancers and super-enhancers and promotes expression of genes important for chondrogenesis, including cartilage matrix protein-coding genes COL2A1, COL4A2, COL9A1, COL11A2 and ACAN, SOX5 and SOX6 (PubMed:[8640233](http://www.uniprot.org/citations/8640233)). Also binds to some promoter regions (By similarity). Plays a central role in successive steps of chondrocyte differentiation (By similarity). Absolutely required for precartilaginous condensation, the first step in chondrogenesis during which skeletal progenitors differentiate into prechondrocytes (By similarity). Together with SOX5 and SOX6, required for overt chondrogenesis when condensed prechondrocytes differentiate into early stage chondrocytes, the second step in chondrogenesis (By similarity). Later, required to direct hypertrophic maturation and block

osteoblast differentiation of growth plate chondrocytes: maintains chondrocyte columnar proliferation, delays prehypertrophy and then prevents osteoblastic differentiation of chondrocytes by lowering beta-catenin (CTNNB1) signaling and RUNX2 expression (By similarity). Also required for chondrocyte hypertrophy, both indirectly, by keeping the lineage fate of chondrocytes, and directly, by remaining present in upper hypertrophic cells and transactivating COL10A1 along with MEF2C (By similarity). Low lipid levels are the main nutritional determinant for chondrogenic commitment of skeletal progenitor cells: when lipids levels are low, FOXO (FOXO1 and FOXO3) transcription factors promote expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation (By similarity). Mechanistically, helps, but is not required, to remove epigenetic signatures of transcriptional repression and deposit active promoter and enhancer marks at chondrocyte-specific genes (By similarity). Acts in cooperation with the Hedgehog pathway-dependent GLI (GLI1 and GLI3) transcription factors (By similarity). In addition to cartilage development, also acts as a regulator of proliferation and differentiation in epithelial stem/progenitor cells: involved in the lung epithelium during branching morphogenesis, by balancing proliferation and differentiation and regulating the extracellular matrix (By similarity). Controls epithelial branching during kidney development (By similarity).

#### **Cellular Location**

Nucleus {ECO:0000255|PROSITE-ProRule:PRU00267, ECO:0000269|PubMed:8640233}

#### **SOX9 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **SOX9 Antibody (N-term) Blocking Peptide - Images**

#### **SOX9 Antibody (N-term) Blocking Peptide - Background**

SOX9 recognizes the sequence CCTTGAG along with other members of the HMG-box class DNA-binding proteins. It acts during chondrocyte differentiation and, with steroidogenic factor 1, regulates transcription of the anti-Muellerian hormone (AMH) gene. Deficiencies lead to the skeletal malformation syndrome campomelic dysplasia, frequently with sex reversal.

#### **SOX9 Antibody (N-term) Blocking Peptide - References**

Malki,S., Cancer Lett. 255 (2), 182-193 (2007)Passeron,T., Proc. Natl. Acad. Sci. U.S.A. 104 (35), 13984-13989 (2007)